With $200M in new cash, Syn­thego wants to be­come the man­u­fac­tur­ing bedrock for CRISPR. But where are its cus­tomers?

Af­ter near­ly a decade de­vel­op­ing CRISPR-based tools to help re­searchers in acad­e­mia and biotech run their ex­per­i­ments, Syn­thego is get­ting in­to a new game: man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER